Table 1. Characteristics of eligible case–control studies included in this meta-analysis.

First author	Year	Country	Ethnicity	Type of disease	Source of controls	Genotyping method	Number of cases	Number of controls	HWE (Control)	NOS score
Zhu et al. [12]	2007	China	Asian	CHD	HB	PCR-RFLP	242	196	0.063	7
Ji et al. [23]	2015	China	Asian	ACS	HB	PCR-RFLP	195	159	0.077	6
Jensen et al. [24]	2009	Denmark	Caucasian	ACS	PB	TaqMan	998	1643	0.888	8
Rimm et al. [25]	1992	America	Caucasian	CAD	PB	PCR	262	519	0.063	8
Colditz et al. [26]	1997	America	Caucasian	CAD	PB	PCR	241	477	0.220	8
Tjonneland et al.(1) [27]	2007	Denmark	Caucasian	CHD	PB	TaqMan	235	763	0.838	8
Tjonneland et al.(2) [27]	2007	Denmark	Caucasian	CHD	PB	TaqMan	763	880	0.997	8
Tang et al. [9]	2008	China	Asian	CAD	HB	PCR-RFLP	265	265	0.103	7
Xie et al. [13]	2015	China	Asian	CAD	HB	PCR	287	367	0.065	7
Solim et al. [28]	2018	Turkey	Caucasian	CAD	HB	TaqMan	74	73	0.545	7
Elnaggar et al. [29]	2019	Egypt	African	CAD	HB	PCR-RFLP	84	42	0.492	8
Dalan et al. [30]	2013	Turkey	Caucasian	CAD	HB	PCR-RFLP	104	76	0.286	7
Cai et al. [14]	2014	China	Asian	CAD	HB	PCR-RFLP	135	166	0.146	7
Toosi et al. [31]	2015	Iran	Asian	CAD	HB	PCR-RFLP	140	80	0.092	8